Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm.

Blood - 1 Oct 2009

Lambert Jonathan R, Everington Tamara, Linch David C, Gale Rosemary E

Abstract excerpt

In essential thrombocythemia (ET), the JAK2-V617F mutation is usually restricted to a subpopulation of neutrophils and platelets, and production of JAK2 wild-type (WT) platelets is not suppressed. Nonmutated precursor cells may, therefore, be susceptible to the acquisition of further JAK2 mutations. We used a common single nucleotide polymorphism (SNP) in the JAK2 coding sequence to genotype V617F alleles...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Erythroid Precursor Cells
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Neutrophils

Share to Phenotype

Share to Polymorphism, Single Nucleotide

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 19541820
DOI: 10.1182/blood-2009-03-209916

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm.PMID 19541820Read ↗

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemiaSemantic proximity Read ↗

Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemiaSemantic proximity Read ↗

Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral blood.Semantic proximity Read ↗

Comparison of clinicopathologic findings according to JAK2 V617F mutation in patients with essential thrombocythemia.Semantic proximity Read ↗

JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone.Semantic proximity Read ↗

The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.Semantic proximity Read ↗

Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia veraSemantic proximity Read ↗

The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemia.Semantic proximity Read ↗

Clinical correlates of JAK2V617F allele burden in essential thrombocythemia.Semantic proximity Read ↗

Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negativeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.